10-12 September 2018 //  Lancaster Royal Hotel, London


Anne-Virginie Eggimann

Anne-Virginie Eggimann

Vice President, Regulatory Science, blubird bio

Anne-Virginie joined bluebird bio in September 2011 to lead the Regulatory Science function. In her role as Vice President, she is responsible for global regulatory strategy and is focused on finding innovative pathways to accelerate the development of bluebird bio’s gene therapy products to meet significant unmet medical needs in serious and life‐threatening conditions. Prior to joining bluebird bio, Anne-Virginie was an Executive Director at Voisin Consulting, leading projects involving the design and implantation of regulatory strategies for medicinal products, with a particular focus on rare diseases including oncology, and advanced therapies.  Her experience spans from early development through commercialization, including lead roles on the registration of several orphan drugs, and regulatory expertise on both sides of the Atlantic.  Anne-Virginie holds a Master of Science in Environmental Health Sciences from the UCLA School of Public Health, as well as a B.S. in Chemical Engineering from the California Institute of Technology. 


2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad